Fundraising Fox

Zetagen

Syracuse, US · Founded 2015 · 1 known investors

Find your way into Zetagen

14 people in our graph share verified history with the Zetagen team — schools, employers, funds. One of them is your warm intro.

Evan Pritchardunlockedknows Joe Loy · together at JStar Capital Investments
×11knows the team · via JStar Capital Investments

Zetagen is a biotechnology company focused on bone-related disease, developing small-molecule therapeutics and approaches targeting bone tumor progression, stem cell activity to promote bone formation, and cancers such as Ewing's sarcoma.

BiotechHealthtechMedical Devices

Founders & leadership

Zetagen was founded in 2015 by Joe C Loy.

JC
Joe C LoyFounderStrategic Business Advisor at JStar Capital Investments
PBPeter B. Finn
Peter B. FinnExecutive
NT
Nikhil Thakur, MDExecutive
DT
David TischlerExecutive
DM
Dr. Margulies

Board

RW
Richard WarburgBoard director
AK
Ashok KaveeshwarBoard director
DB
Donald BrownBoard director

Investors · 1

JStar Capital InvestmentsAustin

Reported raises · per SEC filings

Form D private placements

$26.1M disclosed across 5 rounds · 2017–2025

▶$12.9MraisedNov 2025 · 35 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joe C LoyExecutive Officer, Director
  • Richard WarburgDirector
  • Ashok KaveeshwarDirector
  • Peter B. FinnExecutive Officer
  • Nikhil Thakur, MDExecutive Officer, Director
  • Donald BrownDirector
Offering amount
$13M
Amount sold
$12.9M
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.6MraisedFeb 2023 · 44 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter B. FinnExecutive Officer
  • Joe C LoyDirector
  • Donald BrownDirector
  • Richard WarburgDirector
  • Ashok KaveeshwarDirector
  • Nikhil Thakur, MDExecutive Officer, Director
Offering amount
$15M
Amount sold
$9.6M
First sale
Apr 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$840KraisedDec 2019 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Nikhil Thakur, MDExecutive Officer, Director
  • Joe C LoyExecutive Officer, Director
  • Peter B. FinnExecutive Officer
Offering amount
$8.5M
Amount sold
$840K
Minimum investment
$5K
First sale
Dec 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedDec 2018 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David TischlerExecutive Officer, Director
  • Peter B. FinnExecutive Officer, Director
  • Nikhil Thakur, MDExecutive Officer, Director
Offering amount
$1M
Amount sold
$1M
Minimum investment
$5K
First sale
Jul 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedFeb 2018 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter B. FinnExecutive Officer, Director
  • Nikhil Thakur, MDExecutive Officer, Director
  • David TischlerExecutive Officer, Director
Offering amount
$1.7M
Amount sold
$1.7M
Minimum investment
$10K
First sale
Jan 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2.2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$224.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$301.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Zetagen Therapeutics Closes Over $12M Series B1 Fundingfinsmes.com · Nov 2025Zetagen Therapeutics Closes Oversubscribed Series B1 Round on Strength of Promising Phase 2a Data and Compelling Pipelinebusinesswire.com · Nov 2025Zetagen Therapeutics raises $13M Series B1 for breast cancer treatmentaxios.com · Nov 2025Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet™ (Zeta-BC-003) and ZetaMAST™ (Zeta-MBC-005)for Treatment of Metastatic Bone and Soft Tissue Lesionszetagen.com · Aug 2023Zetagen Therapeutics Raises USD9.79M in Series B Fundingfinsmes.com · Aug 2023Zetagen Therapeutics, Inc. Secures $5.34 Million in Series A Fundingzetagen.com · Feb 2020

Frequently asked questions

What does Zetagen do?
Zetagen is a biotechnology company focused on bone-related disease, developing small-molecule therapeutics and approaches targeting bone tumor progression, stem cell activity to promote bone formation, and cancers such as Ewing's sarcoma.
Who founded Zetagen?
Zetagen was founded by Joe C Loy in 2015.
Who are Zetagen's investors?
Zetagen's investors include JStar Capital Investments.
How much funding has Zetagen raised?
Zetagen has disclosed $26.1M raised across 5 rounds.
Where is Zetagen headquartered?
Zetagen is headquartered in Syracuse, US.